TEVA

Business Context and Reporting Period

Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: Teva is the world's leading generic drug company with a leading position in the U.S. generic market. It also operates a significant Active Pharmaceutical Ingredients (API) business and a proprietary branded drug portfolio, led by Copaxone® for multiple sclerosis. The company operates globally with significant presence in North America, Europe, and Israel.

Key Financial Metrics (2005)

Note: 2004 reported results were significantly impacted by a $596.6 million charge for in-process R&D related to the Sicor acquisition. Excluding this one-time item, 2005 net income increased 11% over 2004.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.4% to $5.25 billion, driven primarily by organic growth in North America and Europe. Currency fluctuations had a negligible impact.
• Profitability Surge: Reported net income increased 223% to $1.07 billion. This dramatic increase is largely due to the absence of the $596.6 million Sicor in-process R&D charge recorded in 2004. On a normalized basis (excluding one-time items), net income grew 11%.
• Product Launches: Significant U.S. launches included generic versions of Allegra® and Zithromax®. Copaxone® global sales exceeded $1 billion for the first time, growing 26% year-over-year.
• Acquisition Activity: While the Sicor acquisition (2004) was integrated, the most significant event was the announcement and subsequent completion (January 2006) of the acquisition of Ivax Corporation for approximately $7.9 billion (accounting value).

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Ivax Acquisition: Teva completed the acquisition of Ivax on January 26, 2006. This transaction significantly expands Teva's footprint in the U.S., Western Europe, and Latin America. Management anticipates significant revenue and cost synergies.
• Financial Impact of Ivax: The acquisition is expected to increase annual amortization expenses by approximately $71.6 million and result in a one-time charge of approximately $1.3 billion for Ivax's in-process R&D in the first quarter of 2006.
• Share Repurchases: Teva spent $379 million in 2005 to repurchase 12.7 million shares.

Risks and Contingencies

• Patent Litigation: Teva faces ongoing litigation regarding generic versions of Allegra®, Neurontin®, OxyContin®, and Zithromax®. Launching products "at risk" prior to final resolution exposes the company to potential damages.
• Competition: Intense competition from brand-name companies (including "authorized generics") and other generic manufacturers continues to drive price erosion.
• Regulatory Environment: Changes in healthcare legislation, particularly regarding Medicare Part D and pricing regulations in Europe and Israel, pose risks to profitability.
• Integration Risks: Successful integration of Ivax is critical to realizing anticipated synergies; failure to integrate could adversely affect operations.

Key Facts for Investor Verification

• Normalized Earnings: Verify the reconciliation of GAAP net income to "normalized" net income to understand the true operational growth trend, as the 2004 comparison is skewed by the Sicor R&D charge.
• Ivax Integration Costs: Monitor Q1 2006 results for the anticipated $1.3 billion in-process R&D charge and increased amortization expenses resulting from the Ivax acquisition.
• Patent Litigation Outcomes: Track the status of litigation regarding Allegra®, Neurontin®, and Zithromax®, as adverse rulings could result in significant damages or injunctions.
• Copaxone® Performance: Verify continued market share growth for Copaxone® against competitors like Tysabri® (pending FDA re-entry) and other MS therapies.
• Debt Structure: Review the new debt instruments issued to finance the Ivax acquisition (Senior Notes and Convertible Debentures) and their impact on future interest expenses.